Can some stomach cancer patients skip chemo after surgery?
NCT ID NCT07751302
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial is testing whether close follow-up is as good as adjuvant chemotherapy for patients with early-stage (IB-IIA) stomach or gastroesophageal junction cancer after curative surgery. Patients are divided into low-risk and high-risk groups based on factors like lymph node involvement. High-risk patients are randomly assigned to either close monitoring or chemotherapy with an oral drug. The goal is to see which approach better prevents cancer recurrence and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tegafur Gimeracil Oteracil Potassium Capsules (an oral chemotherapy drug)
- What this could lead to
- If successful, this could show that some patients with early-stage stomach cancer can safely skip chemotherapy and just be closely monitored, reducing treatment burden while maintaining similar outcomes.
- What could go wrong
- The trial is early and may not show a clear benefit for either approach. Chemotherapy can cause side effects, and close follow-up might miss early recurrence in some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IB-IIA ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Air Force Military Medical University
RECRUITINGXi'an, Shaanxi, 710032, China